| 2026-08-04 | Press release | Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-07-28 | Press release | Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 |
| 2026-06-04 | Press release | Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkin |
| 2026-05-29 | Press release | Arvinas to Present at Jefferies Global Healthcare Conference |
| 2026-05-18 | Press release | Arvinas Employees Give Back During Company-wide Impact Day |
| 2026-05-12 | Press release | Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-12 | Press release | Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepde |
| 2026-05-05 | Press release | Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 |
| 2026-05-01 | Press release | Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer |
| 2026-03-11 | Press release | Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conferen |
| 2026-02-24 | Press release | Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update |
| 2026-02-23 | Press release | Arvinas to Participate in Upcoming Investor Conferences |
| 2026-02-17 | Press release | Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 |
| 2026-02-12 | Press release | Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director |
| 2025-12-06 | Press release | Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination |
| 2025-11-24 | Press release | Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Anton |
| Press release | Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-11-03 | Press release | Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting |
| Press release | Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 |
| 2025-10-24 | Press release | Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mu |
| 2025-10-22 | Press release | Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International C |
| 2025-10-13 | Press release | Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Onc |
| 2025-10-05 | Press release | Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 Interna |
| 2025-10-01 | Press release | Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s |
| Press release | Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| Press release | Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 |
| 2025-06-13 | Press release | Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congres |
| 2025-06-05 | Press release | Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) |
| 2025-06-02 | Earnings deck | Phase 3 VERITAC-2 Trial Results Presentation |
| Press release | Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-04-29 | Proxy statement | Arvinas 2025 Proxy Statement |
| Press release | Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 |
| 2025-04-28 | Press release | Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association |
| 2025-04-23 | Press release | Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Soci |
| 2025-04-21 | Press release | Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® |
| 2025-03-27 | Press release | Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases |
| 2024-12-10 | Press release | Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abem |
| 2024-11-25 | Press release | Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium |
| Press release | Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| Press release | Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, Octob |